Adult acne is not a teenage problem that followed you.  It is a different condition entirely. Treat it that way.

If you are treating adult acne with teenage acne products, you are not just using the wrong formula. You are using a formula designed for a completely different biological condition.

Why Adult Acne Is Different

Teenage acne is primarily driven by a surge in androgen hormones during puberty, which increases sebum production across the whole face. It tends to present as widespread whiteheads, blackheads, and inflammatory lesions, and it often improves significantly once hormone levels stabilise.

Adult acne in women is primarily hormonal in a different way. It is driven by cyclical androgen fluctuations tied to the menstrual cycle, perimenopause, stress cortisol, and insulin response. It tends to concentrate in the lower face and jawline, presents as deeper cystic lesions rather than surface whiteheads, and is significantly more prone to leaving PIH marks because the skin’s healing capacity is already being compromised by the other changes happening at 35+.

The Collagen Complication

Here is what makes adult acne uniquely difficult: it is happening at exactly the same time as collagen loss.

Collagen production begins declining in the late twenties and accelerates significantly around 35. Estimates from collagen synthesis research suggest women may lose up to 30% of dermal collagen in the first five years after menopause, with a slower ongoing decline from the mid-thirties (Varani et al., American Journal of Pathology, 2006). The skin becomes thinner, less elastic, and heals more slowly from inflammatory events.

This means that the same inflammatory acne lesion that would have healed in two weeks at 20 may take six weeks at 37, leave a deeper PIH mark, and cause more collagen disruption in the surrounding tissue. The acne is not necessarily worse. The conditions it is occurring in are significantly more fragile.

Why Teenage Acne Products Make It Worse

Teenage acne products are formulated for skin with high sebum production, high cell turnover, and high resilience. They are often aggressive: high-percentage benzoyl peroxide, strong AHA cycling, drying clay formulas, alcohol-based toners.

Adult skin at 35+ does not have the resilience to recover quickly from these treatments. Aggressive exfoliation creates micro-inflammation that slows collagen repair. Drying actives compromise a barrier that is already thinner than it was at 20. High-percentage benzoyl peroxide, while effective at killing P. acnes, can trigger significant PIH in melanin-rich skin that is now also producing less collagen to repair the damage.

The cycle looks like this: aggressive treatment, skin barrier disruption, more sensitivity and reactivity, more acne triggers, more PIH, more aggressive treatment. It is a loop designed for someone else’s skin at someone else’s age.

What Adult Acne-Prone Skin Actually Needs

1. Barrier support first. Everything else works better when the barrier is intact — including every active you apply on top of it.
2. Gentle actives, used consistently. Willow bark clears pores and reduces sebum daily, without the barrier disruption that high-concentration BHA causes on melanin-rich skin.
3. Anti-inflammatory ingredients to break the breakout-to-mark cycle. Bisabolol targets the NF-κB pathway that turns inflammation into pigment. Calendula supports it.
4. Peptides alongside the acne treatment. Acetyl Hexapeptide-8 and Hexapeptide-11 signal collagen production without any irritation mechanism — appropriate for inflamed skin.
5. Adult hormonal acne is managed, not cured. Consistent gentle support over time outperforms aggressive short-term treatment — especially on skin where every flare risks a mark that takes months to fade.

Sources: Collier et al., J Am Acad Dermatol (2008) — pubmed.ncbi.nlm.nih.gov/17945383 · PMC 12584016, Prevalence and Characteristics of Adult Female Acne (2025) — pmc.ncbi.nlm.nih.gov/articles/PMC12584016 · Varani et al., American Journal of Pathology (2006) — doi.org/10.2353/ajpath.2006.060281 · Auffret et al., Acta Derm Venereol (2025) — doi.org/10.2340/actadv.v105.42925